Skip to content
Search

Latest Stories

High Court dismissed BGMA's claim on being excluded from VPAS negotiation

The High Court has dismissed the British Generic Manufacturers Association (BGMA)'s claim on being excluded from ongoing negotiations between the government and industry to agree a new Voluntary Scheme for medicine pricing and access (VPAS).

The association had sought a judicial review of the Department of Health and Social Care’s (DHSC) decision to negotiate a new Voluntary Scheme for branded medicines with the Association of the British Pharmaceutical Industry (ABPI) in April.


Commenting on the result of the case, Richard Torbett, Chief Executive of the ABPI said: “For over 60 years the ABPI has acted as the representative industry body for negotiations on the Voluntary Scheme for branded medicines – a responsibility we take extremely seriously – and one which has been reaffirmed by today’s judgment.

“While we were disappointed that the BGMA decided to take this action – we recognise their decision was driven by the extreme challenge placed on all parts of the industry from the surge in the branded medicine payment rates.

“The solution to these problems must be a completely new and sustainable approach to medicines provision in the UK which rapidly brings industry revenue payments in line with comparator countries to unlock investment and growth.”

Earlier while seeking judicial review Mark Samuels, Chief Executive of BGMA commented: “The Government has decided not to involve the trade body representing these medicine suppliers in its negotiations on the voluntary scheme for branded medicine pricing (VPAS).

“We are deeply concerned by this decision. It has left us no choice but to take legal action.”

“While not all generic drugs fall within VPAS, four out of ten products in the current scheme are branded generics or biosimilars. As the representative trade body for both generic and biosimilar UK manufacturers, we must play a full part in the VPAS negotiations for the next period of the scheme from 2024 to 2028.”

“The VPAS tax has risen five-fold in under two years, an unprecedented tax increase. Yet our sector currently has no input into the negotiations on future schemes or rates; this is untenable as any decisions made on VPAS could significantly define the future of our sector in the UK and its ability to supply the NHS.

He also stated: "We also do not believe ABPI – who are the only party with whom the Government currently negotiates – can adequately represent or balance the interests of the off-patent sector in these negotiations."

More For You

Kinnock highlights employers’ role in making community pharmacy jobs attractive

The new funding uplift our commitment to rebuilding the sector: Kinnock

Kinnock: ‘Employers have a key role in making community pharmacy jobs attractive’

Health minister Stephen Kinnock has emphasised that employers have a crucial role to play in retaining staff and making careers in community pharmacy more attractive.

His comments came in response to a written question from Victoria Collins MP, the Liberal Democrat spokesperson for science and technology, who asked what steps the Department of Health and Social Care is taking to address staff shortages and prevent the closure of local pharmacies.

Keep ReadingShow less
MHRA approves Pfizer Hympavzi (marstacimab) for haemophilia treatment

Marstacimab is currently being assessed by NICE and the Scottish Medicines Consortium for use on the NHS

gettyimages

Marstacimab approved for haemophilia treatment, Pfizer aims for NHS availability

The Medicines and Healthcare products Regulatory Agency (MHRA) has approved Hympavzi(marstacimab) to prevent or reduce bleeding in patients aged 12 years and older, weighing at least 35kg, who have severe haemophilia A or B.

Developed by Pfizer scientists, this groundbreaking treatment is the first of its kind to target a protein involved in the blood clotting process.

Keep ReadingShow less
​Pope Francis

Pope Francis at the Vatican on December 4, 2024.

Photo by FILIPPO MONTEFORTE/AFP via Getty Images

His Holiness Mahant Swami Maharaj offers condolences to Catholic community following Pope Francis' passing

His Holiness Mahant Swami Maharaj, the spiritual leader and president of the Bochasanwasi Akshar Purushottam Swaminarayan Sanstha (BAPS), has expressed heartfelt condolences to the Catholic community worldwide following the passing of Pope Francis on Monday.

In a formal letter addressed to the members of the Roman Catholic Church, Mahant Swami Maharaj conveyed the deep sorrow of the BAPS Swaminarayan Hindu fellowship, acknowledging the Pope's passing as “a profound loss to the Catholic community and Christians around the world.”

Keep ReadingShow less
Pharmacies in Northern Ireland distribute free booklets to raise cancer awareness

Dr Anna Cullen, Public Health Registrar at the Public Health Agency and Clare Conroy, Community Pharmacist from Meigh Pharmacy in Co Down.

Photo credit: Community Pharmacy Northern Ireland

Pharmacies in Northern Ireland help raise cancer awareness

Community pharmacies across Northern Ireland are distributing a free information booklet to help raise public awareness of the signs and symptoms of cancer and promote early diagnosis.

The initiative is part of the ‘Be Cancer Aware’ campaign, which has been running in pharmacies since April and will continue through May as part of the Living Well service.

Keep ReadingShow less
CPE invites pharmacy owners to share their views on new CPCF funding settlement

What do you think should be the next priority for the Government?

gettyimages

Pharmacy owners asked to share their views on new CPCF arrangements

Community Pharmacy England (CPE) is urging pharmacy owners to share their views on the new Community Pharmacy Contractual Framework (CPCF) funding settlement ahead of its next full Committee meeting, scheduled for 30 April–1 May.

The Committee said it had agreed to the settlement "reluctantly," acknowledging that it represents a significant shift after years of real-terms funding cuts, while admitting that it’s “still not sufficient to match the continued scale of pressures facing pharmacy businesses.”

Keep ReadingShow less